Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa (NCT00692185) | Clinical Trial Compass
CompletedPhase 2
Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa
United States23 participantsStarted 2005-10
Plain-language summary
This study will evaluate the effectiveness of the antipsychotic medication olanzapine in treating outpatients with anorexia nervosa.
Who can participate
Age range16 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Meets DSM-IV criteria (not including amenorrhea) for AN
* Body mass index (BMI) less than 19 kg/m2 and greater than 14 kg/m2
* Patient (or family if the patient is a minor) refuses hospitalization
* Free of psychotropic medication (4 weeks medication free for fluoxetine and antipsychotic medication; 2 weeks medication free for all others) OR on a stable dose of an SSRI or SNRI (venlafaxine) for 4 weeks before study entry
* Prior treatment of AN
Exclusion Criteria:
* Any medical or psychiatric problem requiring urgent attention and/or any significant comorbid illness not likely to benefit from proposed treatments
* Allergy to olanzapine
* Significant orthostatic high blood pressure
* Recent commencement of psychotherapy in the community
* Diabetes mellitus, with a fasting serum glucose greater than 120 mg/dL or nonfasting serum glucose greater than 140 mg/dL
* Known history of current or past jaundice
* Known history of narrow angle glaucoma
* Active substance abuse or dependence
* Schizophrenia, schizophreniform disorder, or bipolar illness
* Movement disorder or presence of tics
* History of tardive dyskinesia
* History of seizures
* Pregnant